Navigation
Navigation

Capricorn Health-tech Fund

The Capricorn Health-tech Fund (CHF) focuses on human health-technology investments. Health-technologies relate to the prevention, the diagnosis and the treatment of diseases.

Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication

News
- 20/06/2019
Ghent, Belgium: 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over…
Read more

Leading Austrian Clinic, Klinik Pirawarth, Provides Positive Feedback on its First Nexstim NBT® System for Treatment of Depression and Pain

News
- 18/06/2019
Helsinki, Finland: 18 June 2019 - Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD) - announces that…
Read more

Team
Dr Jos B. Peeters
Chairman of the Executive Committee - Responsible for venture capital, finance and IT
Dr Katya Smirnyagina
Executive Director Capricorn Health-tech Fund

Portfolio

Success stories

Ogeda

Ogeda [Belgium] is a drug development company with a chemistry service business focusing on discovery of small molecules targeting GPCRs.